HIV-2 Protease resistance defined in yeast cells
Retrovirology, 2006 Background Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue.
Raoult Didier +3 more
doaj +1 more source
Sensors, 2013 To effectively fight against the human immunodeficiency virus infection/ acquired immunodeficiency syndrome (HIV/AIDS) epidemic, ongoing development of novel HIV protease inhibitors is required.
Rok Gaber +3 more
doaj +1 more source
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdon: multicentre cohort study [PDF]
, 2005 Objectives: To investigate whether there is evidence that an increasing proportion of HIV infected patients is starting to experience increases in viral load and decreases in CD4 cell count that are consistent with exhaustion of available treatment ...
Bhagani, S +13 more
core +2 more sources
HIV Protease Inhibitors Impact on Apoptosis [PDF]
Medicinal Chemistry, 2008 HIV protease inhibitors are the backbone of HIV therapy. In addition to blocking intracellular HIV protease and dramatically decreasing viral burden, the protease inhibitors also regulate apoptosis. A growing body of data has confirmed the immunomodulatory effects of HIV protease inhibitors which block CD4+ and CD8+ T cell death in models of HIV ...
Stacey A. Rizza, Andrew D. Badley
openaire +3 more sources
HIV-1 Protease: Structural Perspectives on Drug Resistance
Viruses, 2009 Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms
Irene T. Weber, Johnson Agniswamy
doaj +1 more source
Personalizing HIV therapy, mission impossible? [PDF]
, 2012 Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core +1 more source
Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals [PDF]
, 2006 Until today, the susceptibility of human immunodeficiency virus type 2 (HIV-2) to protease and nucleosidic reverse-transcriptase inhibitors (PI and NRTI, respectively) has not been clearly documented. In this report we studied HIV-2 proviral sequences (n
Esteves, A. +6 more
core +1 more source
HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
European Journal of Medical Research, 2009 End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj +1 more source
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. [PDF]
, 2005 Highly active antiretroviral therapy has substantially improved prognosis in human immunodeficiency virus (HIV). However, the integration of proviral DNA, development of viral resistance, and lack of permeability of drugs into sanctuary sites (e.g ...
Back, DJ +9 more
core +1 more source
Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay. [PDF]
, 2011 Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide.
Agudelo, Juliet +10 more
core +1 more source